Blueprint Medicines Corporation (BPMC): Product News News

BPMC – Reports proof-of-concept data for highly selective RET Inhibitor BLU-667.

Key Facts Surrounding This News Item

  • BPMC had a POWR Rating of B (Buy) coming into today.
  • BPMC was 5.38% above its 10-Day Moving Average coming into today.
  • BPMC was 4.47% above its 20-Day Moving Average coming into today.
  • BPMC was 9.41% above its 50-Day Moving Average coming into today.
  • BPMC was 18.82% above its 100-Day Moving Average coming into today.
  • BPMC was 39.91% above its 200-Day Moving Average coming into today.
  • BPMC had returned +31.26% year-to-date leading up to today’s news, versus a -0.24% return from the benchmark S&P 500 during the same period.

More Info About Blueprint Medicines Corporation (BPMC)

Blueprint Medicines Corporation makes kinase drugs to treat patients with genomically defined diseases. The company was founded in 2008 and is based in Cambridge, Massachusetts. View our full BPMC ticker page with ratings, news, and more.

Try Premium Today!

Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

BPMC at a Glance

BPMC Current POWR Rating™
Overall POWR Rating™
BPMC Current Price $71.59 2.84%
More BPMC Ratings, Data, and News

BPMC Price Reaction

The day of this event (Apr. 16, 2018)
BPMC Closing Price$86.47 12.64%
BPMC Volume1,720,900
311.75% from avg
Leading up to this event
BPMC 1-mo return0.54%
After this event
BPMC 1-day return12.23%
BPMC 3-day return18.89%
BPMC 5-day return25.09%

BPMC Price Chart

More Blueprint Medicines Corporation (BPMC) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All BPMC News
Page generated in 1.2062 seconds.